Learn About Our Early and Metastatic Breast Cancer Research
With the help of research study participants, we are learning potential new ways to improve Breast Cancer health outcomes.
Learn MoreThe main purpose of this study is to evaluate the safety and efficacy of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in participants with stage IV non small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Del19 and L858R). Safety and tolerability of ramucirumab in combination with erlotinib will be assessed in the first portion (Part A) before proceeding to the second portion of this study (Part B). The purpose of Part C is to determine the efficacy and safety of ramucirumab in combination with gefitinib in previously untreated East Asian participants with EGFR mutation-positive metastatic NSCLC and of ramucirumab in combination with osimertinib in participants whose disease progressed on ramucirumab and gefitinib and that have T790M - positive metastatic NSCLC.
Participant must have diagnosis of stage IV NSCLC
Participant must have documented evidence of a tumor with an activating EGFR mutation and be eligible for first-line treatment with erlotinib
Participant must be able to provide adequate archived stage IV NSCLC tissue sample or tissue samples other than stage IV NSCLC may be acceptable (optional for part C)
Participant must have ECOG performance status of 0 or 1 where 0 = Fully active, able to carry on all pre-disease performance without restriction and 1 = Restricted in physically strenuous activity but able to walk and carry out light work, e.g., light house work, office work
Participant must have one measurable lesion
Participant must not have a known T790M mutation
Participant must not have brain metastases
Participant must not have a history of significant bleeding disorders or blood clots in the arteries
Participant must not have any known significant abnormalities of the surface of the eye
With the help of research study participants, we are learning potential new ways to improve Breast Cancer health outcomes.
Learn MoreBy volunteering to take part in Prostate cancer clinical trials, you may be able to play an important role in the research and development of potential new treatments and medicines. We understand that when you or a loved one take part in a clinical trial, it is a big decision. It is important for you to understand why the research is being carried out and what taking part will mean for you. Learn more about Lilly
Prostate Cancer ResearchLilly has been involved in cancer research for more than fifty years, working to improve the lives of people living with cancer. Learn more about cancer research at Lilly and how you can make an impact.
Learn MoreA clinical trial is a scientific study. It helps us learn if a new medicine or treatment works and how it works. Clinical trials can also be called clinical research studies. Learn more about clinical research studies and what to expect when taking part in a clinical trial.